Interpol is on the hunt for fugitives accused of such crimes as ivory smuggling. illegal logging, and trafficking live animals
The cosmetics retailer is facing a lawsuit
The oil market has moved beyond the Keystone XL pipeline
A new tool detects computer malware that’s watching your every move
The provider of high-interest business loans nears an IPO, on the strength of its data-powered credit analysis—and a network of shady brokers
Nike expects revenue from women to outpace its men's business.
Twist, stretch, twirl: a day in the life of a candy cane
Educational Credit Management, a guarantor and collector of student loans, wants to buy 56 campuses from Corinthian Colleges
The novelty items are hot for retailers large and small
Founder: Dr. Mark Pruzanski
VC Investment over the last four quarters: $25 million
Founded in 2002, the 25-employee biopharmaceutical company is in the process of developing therapeutic treatment of chronic fibrotic and metabolic diseases. Despite the downturn, the company raised significant funding this year. Sticking to a tight budget, Intercept expects to have enough cash resources to fund its operations until 2010.
Key to startup success: "Be persistent. Intercept was founded just before the last major downturn for biotech, which lasted through 2003 and venture capital completely dried up for new early-stage startups. [We] remained passionately dedicated to the company and persisted even though it took more than a year to secure financing."